Use of enoxaparin, a low molecular weight heparin, in elective hip surgery
Planes, A.; Vochelle, N.; Bouthier, J.; Fagola, M.; Bellaud, M.
Seminars in Thrombosis and Hemostasis 17(Suppl 3): 296-303
1991
ISSN/ISBN: 0094-6176 PMID: 1661439 Document Number: 368365
Document emailed within 1 workday
Related Documents
Akanmu, A.S.; Nnodu, O.E.; Giwa, S.O.; Salako, L.A.; Akinsete, I.; Adebule, G.T.; Adekoya-Cole, T.O.; Odunubi, O.O. 2004: Efficacy and safety of enoxaparin, a low molecular weight heparin in the prevention of deep vein thrombosis in Nigerian patients after orthopaedic surgery African Journal of Medicine and Medical Sciences 33(4): 335-340Forbes, C.D. 1989: Prevention of deep vein thrombosis--use of the low molecular weight heparin enoxaparin British Journal of Clinical Practice 43(11): 396-400
Brieger, D.; Dawes, J. 1994: Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane) Thrombosis and Haemostasis 72(2): 275-280
Gris, J.C.; Neveu, S.; Tailland, M.L.; Courtieu, C.; Marès, P.; Schved, J.F. 1995: Use of a low-molecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity Thrombosis and Haemostasis 73(3): 362-367
Brieger, D.; Dawes, J. 1996: Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin Thrombosis and Haemostasis 75(5): 740-746
Cohen, M. 2000: Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes Journal of Invasive Cardiology 12 Suppl E: E5
Pimentel Filho, W.A. 1995: The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty Arquivos Brasileiros de Cardiologia 65(6): 517-518
Hull, R.D.; Pineo, G.F.; Stein, P.D.; Mah, A.F.; MacIsaac, S.M.; Dahl, O.E.; Ghali, W.A.; Butcher, M.S.; Brant, R.F.; Bergqvist, D.; Hamulyák, K.; Francis, C.W.; Marder, V.J.; Raskob, G.E. 2001: Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review Archives of Internal Medicine 161(16): 1952-1960
Grunebaum, L.; Fricker, J.P.; Wiesel, M.L.; Vergnes, Y.; Kapps, J.; Cazenave, J.P. 1987: Preliminary results of a randomized trial comparing the efficacy of standard heparin with that of fragmine, a low molecular weight heparin, in the prevention of postoperative thrombosis in cancer surgery Journal des Maladies Vasculaires 12 Suppl B: 102-104
Kumar, A.; Nainiwal, S.; Sreenivas, B. 2003: Intravitreal low molecular weight heparin in PVR surgery Indian Journal of Ophthalmology 51(1): 67-70
Borris, L.C.; Lassen, M.R.; Jensen, H.P.; Andersen, B.S.; Poulsen, K.A. 1994: Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Clinical and economic considerations International Journal of Clinical Pharmacology and Therapeutics 32(5): 262-268
Evarts, C.M.; Feil, E.I. 1971: Thromboembolism after elective surgery of the hip. Detection, natural history, prophylaxis, and results with low molecular weight dextran Orthopedic Clinics of North America 2(1): 167-174
Nikolov, A.; Kovachev, I.; Petkov, I.; Dimitrov, A. 2000: Low-molecular-weight heparin. Prophylaxis and treatment of thromboembolisms in surgery and obstetrics Akusherstvo i Ginekologiia 39(3): 35-40
Schwarz, B.; Mittelmeier, H. 1988: Initial clinical experiences with low molecular weight heparin in the prevention of thrombosis in orthopedic surgery Aktuelle Traumatologie 18(5): 226-232
Jørgensen, P.S.; Knudsen, J.B.; Broeng, L.; Josephsen, I.L.; Bjerregaard, P.; Hagen, K.K.; Jørgensen, P.K.; Tørholm, C. 1993: The thromboprophylactic effect of low molecular weight heparin (Fragmin) in hip fracture surgery. a placebo controlled trial Ugeskrift for Laeger 155(10): 706-708
Palareti, G.; Legnani, C.; Bianchini, B.; Guazzaloca, G.; Maccaferri, M.; Marabini, A.; De Iaco, P.; Marcozzi, S.; Mancini, L.; Orlandi, C. 1989: Pharmacodynamic effects on blood coagulation of a new low molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecological surgery patients International Angiology: a Journal of the International Union of Angiology 8(1): 47-52
Wei, N.; Qi, Y.; Yang, H.; Guo, L. 2018: Clinical observation of the efficacy of low-molecular-weight heparin calcium in prophylaxis of the deep venous thrombosis following the gynecological tumor surgery Pakistan Journal of Pharmaceutical Sciences 31(6(Special): 2835-2839
Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264